FindTrial
Sign In

Contrast-enhanced endoscopic ultrasound versus CT scan in the evaluation of focal pancreatic lesions.

Contrast-enhanced endoscopic ultrasound versus CT scan in the evaluation of focal pancreatic lesions. - CE-EUS versus CT scan in pancreatic lesions

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35110
Enrollment
100
Registered
2010-10-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic tumor

Interventions

A contrast agent will be administred intravenously

Sponsors

Maasstadziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Individuals with focal pancreatic lesions documented by CT scan

Exclusion criteria

Exclusion criteria: Patients with unstable coronary artery disease Known allergy to SonoVue

Design outcomes

Primary

MeasureTime frame
Determine the sensitivity of contrast enhanced EUS—

Secondary

MeasureTime frame
Compare the sensitivity of contrast enhanced EUS with that of CT scan—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)